See more : Sunwels Co.,Ltd. (9229.T) Income Statement Analysis – Financial Results
Complete financial analysis of BioVaxys Technology Corp. (BVAXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVaxys Technology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Arrowhead Seperation Engineeri (ARROWHEAD.BO) Income Statement Analysis – Financial Results
- Ourgame International Holdings Limited (6899.HK) Income Statement Analysis – Financial Results
- Morgan Stanley (MS-PI) Income Statement Analysis – Financial Results
- Country Condo’s Limited (COUNCODOS.BO) Income Statement Analysis – Financial Results
- Hengdian Group Tospo Lighting Co., Ltd. (603303.SS) Income Statement Analysis – Financial Results
BioVaxys Technology Corp. (BVAXF)
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.73K | 962.71K | 726.06K | 238.77K | 0.00 |
| General & Administrative | 2.11M | 2.94M | 4.00M | 775.10K | 229.91K |
| Selling & Marketing | 156.88K | 174.30K | 1.72M | 84.51K | 0.00 |
| SG&A | 2.27M | 3.12M | 5.72M | 859.61K | 229.91K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Cost & Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Interest Income | 24.85K | 15.77K | 7.66K | 137.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.40M | 3.80M | 5.98M | 1.01M | 183.34K |
| EBITDA | 0.00 | 3.58M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.40M | 3.58M | -6.42M | -1.09M | -229.70K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.28M | -7.92M | -478.68K | -93.55K | -33.54K |
| Income Before Tax | -7.69M | -11.73M | -6.46M | -1.10M | -230.12K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 7.64M | 9.93K | 71.69K | 29.66 |
| Net Income | -7.69M | -11.73M | -6.46M | -1.17M | -230.12K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| EPS Diluted | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| Weighted Avg Shares Out | 134.15M | 98.18M | 82.93M | 30.05M | 11.02M |
| Weighted Avg Shares Out (Dil) | 134.14M | 98.18M | 82.93M | 28.21M | 10.39M |
BioVaxys to present a poster on its coronavirus vaccine candidate BVX-0320 at ISIRV-WHO virtual conference
BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
BioVaxys Technology says DTH response persists for at least one year after coronavirus exposure or vaccination
BioVaxys Closes Final Tranche Of Non-Brokered Private Placement
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
BioVaxys Technology closes first tranche of non-brokered private placement to raise $838,675 in gross proceeds
BioVaxys Announces Non-Brokered Private Placement
Source: https://incomestatements.info
Category: Stock Reports